Compare
Xtant Medical Holdings, Inc. vs Neuronetics, Inc. vs Orasure Technologies Inc vs Anika Therapeutics, Inc.
| Latest fiscal year | Xtant Medical Holdings, Inc. XTNT | Neuronetics, Inc. STIM | Orasure Technologies Inc OSUR | Anika Therapeutics, Inc. ANIK |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $133.93M | $149.16M | $115.02M | $112.82M |
| Revenue growth (YoY) | +14.2% | +99.2% | -38.1% | -5.9% |
| Gross margin | 62.9% | 48.5% | 41.9% | 56.6% |
| Operating margin | 5.4% | -21.1% | -62.6% | -9.8% |
| Net margin | 3.7% | -26.1% | -59.8% | -9.6% |
| Net income | $4.97M | -$39.00M | -$68.73M | -$10.88M |
| EPS (Diluted) | $0.03 | -$0.59 | -$0.94 | -$0.76 |
| Operating cash flow | $12.55M | -$20.37M | -$49.02M | $11.19M |
| Free cash flow | $10.16M | -$21.18M | -$53.22M | $4.36M |
| Cash & equivalents | $17.05M | $28.13M | $199.28M | $57.48M |
| Total assets | $94.14M | $141.55M | $403.17M | $190.27M |
| Total liabilities | $43.19M | $115.31M | $62.34M | n/a |
| Shareholders' equity | $50.95M | $22.38M | $340.83M | $143.47M |
| Return on year-end equity | 9.8% | -174.3% | -20.2% | -7.6% |
| Shares outstanding | 140.04M | 68.99M | 70.39M | 13.89M |
Revenue, most recent five fiscal years
| Fiscal year | Xtant Medical Holdings, Inc. | Neuronetics, Inc. | Orasure Technologies Inc | Anika Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $133.93M Ended 2025-12-31 | $149.16M Ended 2025-12-31 | $115.02M Ended 2025-12-31 | $112.82M Ended 2025-12-31 |
| 1 year earlier | $117.27M Ended 2024-12-31 | $74.89M Ended 2024-12-31 | $185.83M Ended 2024-12-31 | $119.91M Ended 2024-12-31 |
| 2 years earlier | $91.30M Ended 2023-12-31 | $71.35M Ended 2023-12-31 | $405.47M Ended 2023-12-31 | $120.79M Ended 2023-12-31 |
| 3 years earlier | $57.97M Ended 2022-12-31 | $65.21M Ended 2022-12-31 | $387.48M Ended 2022-12-31 | $113.83M Ended 2022-12-31 |
| 4 years earlier | $55.26M Ended 2021-12-31 | $55.31M Ended 2021-12-31 | $233.67M Ended 2021-12-31 | $147.79M Ended 2021-12-31 |